NCT03704428View on ClinicalTrials.gov

Safety, Tolerability and PK of SHR1314 in axSpA

PHASE1CompletedINTERVENTIONAL
Enrollment

45

Participants

Timeline

Start Date

April 19, 2018

Primary Completion Date

January 14, 2020

Study Completion Date

January 14, 2020

Conditions
Axial Spondyloarthritis
Interventions
DRUG

SHR-1314

Pharmaceutical form: Injection solution. Route of administration: subcutaneous injection.

Trial Locations (1)

Unknown

Jianwen Chen, Shanghai

All Listed Sponsors
lead

Jiangsu HengRui Medicine Co., Ltd.

INDUSTRY

NCT03704428 - Safety, Tolerability and PK of SHR1314 in axSpA | Biotech Hunter | Biotech Hunter